Avalo Therapeutics (AVTX) News Today $9.29 -0.05 (-0.54%) Closing price 04:00 PM EasternExtended Trading$9.29 0.00 (0.00%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Avalo Therapeutics, Inc. $AVTX Shares Purchased by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesAugust 27 at 7:00 AM | globenewswire.comBrokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $30.00August 27 at 2:29 AM | americanbankingnews.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Buy" from BrokeragesAugust 24, 2025 | marketbeat.com312,779 Shares in Avalo Therapeutics, Inc. $AVTX Purchased by RWA Wealth Partners LLCAugust 21, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight RecommendationAugust 16, 2025 | msn.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest UpdateAugust 16, 2025 | marketbeat.comAvalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAugust 15, 2025 | msn.comAvalo gains as Cantor initiates with bullish view on lead assetAugust 15, 2025 | msn.comAvalo Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comAvalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results, Misses Estimates By $0.49 EPSAugust 11, 2025 | marketbeat.comAvalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business UpdatesAugust 8, 2025 | finanznachrichten.deAvalo Reports Second Quarter 2025 Financial Results and Recent Business UpdatesAugust 7, 2025 | globenewswire.comAvalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on MondayAugust 5, 2025 | marketbeat.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Recommendation of "Buy" by BrokeragesJuly 28, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Stock Price Down 0.6% - What's Next?July 25, 2025 | marketbeat.comNASDAQ:AVTX Financials | Avalo Therapeutics Inc - Investing.comJuly 11, 2025 | investing.comAvalo Adds Dr. Rita Jain to Board as LOTUS Trial AdvancesJuly 3, 2025 | msn.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesJune 23, 2025 | globenewswire.comAvalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of DirectorsJune 18, 2025 | globenewswire.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 45.8% in MayJune 15, 2025 | marketbeat.comH.C. Wainwright upgrades Avalo Therapeutics stock to buyJune 4, 2025 | uk.investing.comAvalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis SuppurativaMay 13, 2025 | nasdaq.comAVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly EarningsMay 13, 2025 | nasdaq.comAvalo Therapeutics: Avalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 12, 2025 | finanznachrichten.deAvalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 12, 2025 | globenewswire.comDeep Track Capital LP Sells 100,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 9, 2025 | marketbeat.comBVF Inc. IL Grows Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 6, 2025 | marketbeat.comAllostery Investments LP Buys Shares of 73,314 Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 4, 2025 | marketbeat.comGeode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 4, 2025 | marketbeat.comAvalo Therapeutics to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Affinity Asset Advisors LLCApril 17, 2025 | marketbeat.comSeven new option listings and one option delisting on April 16thApril 17, 2025 | markets.businessinsider.comAvalo Therapeutics Reports 2024 Financial ResultsApril 15, 2025 | tipranks.comAvalo Therapeutics (AVTX) to Release Earnings on FridayMarch 28, 2025 | marketbeat.comAvalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by AnalystsMarch 26, 2025 | marketbeat.comAvalo Therapeutics initiated with a Buy at JefferiesMarch 26, 2025 | markets.businessinsider.comAvalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel NicolausMarch 26, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Jefferies Financial GroupMarch 26, 2025 | marketbeat.comAvalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardMarch 26, 2025 | globenewswire.comStifel initiates Avalo Therapeutics stock with a Buy ratingMarch 26, 2025 | investing.comStifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationMarch 25, 2025 | msn.comWedbush Research Analysts Lift Earnings Estimates for AVTXMarch 24, 2025 | marketbeat.comEquities Analysts Set Expectations for AVTX Q1 EarningsMarch 24, 2025 | marketbeat.comQ1 EPS Estimates for Avalo Therapeutics Lifted by WedbushMarch 22, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Given Neutral Rating at HC WainwrightMarch 21, 2025 | marketbeat.comAvalo Therapeutics (NASDAQ:AVTX) Given Outperform Rating at WedbushMarch 21, 2025 | marketbeat.comAvalo Therapeutics: Avalo Reports 2024 Financial Results and Recent Business UpdatesMarch 20, 2025 | finanznachrichten.deAvalo Reports 2024 Financial Results and Recent Business UpdatesMarch 20, 2025 | globenewswire.com Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTX Media Mentions By Week AVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTX News Sentiment▼1.111.03▲Average Medical News Sentiment AVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTX Articles This Week▼51▲AVTX Articles Average Week Get the Latest News and Ratings for AVTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Avalo Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alumis News Today Arcturus Therapeutics News Today Evolus News Today Bicycle Therapeutics News Today Tectonic Therapeutic News Today Nanobiotix News Today Cullinan Therapeutics News Today Prime Medicine News Today Prothena News Today Autolus Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access